Argenx (ARGX)
(Delayed Data from NSDQ)
$499.67 USD
-16.51 (-3.20%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $499.41 -0.26 (-0.05%) 7:58 PM ET
1-Strong Buy of 5 1
F Value F Growth A Momentum F VGM
argenex SE (ARGX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$537.00 | $610.00 | $416.00 | 4.03% |
Price Target
Based on short-term price targets offered by 20 analysts, the average price target for argenex SE comes to $537.00. The forecasts range from a low of $416.00 to a high of $610.00. The average price target represents an increase of 4.03% from the last closing price of $516.18.
Analyst Price Targets (20)
Broker Rating
argenex SE currently has an average brokerage recommendation (ABR) of 1.32 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 25 brokerage firms. The current ABR compares to an ABR of 1.48 a month ago based on 25 recommendations.
Of the 25 recommendations deriving the current ABR, 21 are Strong Buy, representing 84% of all recommendations. A month ago, Strong Buy represented 76%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/ARGX.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 21 | 21 | 19 | 18 | 19 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 4 | 4 | 6 | 6 | 6 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.32 | 1.32 | 1.48 | 1.50 | 1.48 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/29/2024 | Robert W. Baird & Co. | Joel L Beatty | Strong Buy | Strong Buy |
7/26/2024 | UBS | Xian Deng | Hold | Hold |
7/26/2024 | Guggenheim Securities | Yatin Suneja | Strong Buy | Strong Buy |
7/23/2024 | Not Identified | Not Identified | Hold | Strong Buy |
7/22/2024 | Wedbush Securities | David M Nierengarten | Strong Buy | Strong Buy |
6/27/2024 | Evercore Partners | Gavin Clark-Gartner | Strong Buy | Strong Buy |
6/24/2024 | Goldman Sachs | Rajan Sharma | Not Available | Strong Buy |
6/24/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
6/24/2024 | Truist Securities | Joon Lee | Strong Buy | Strong Buy |
6/24/2024 | Wells Fargo Securities | Derek C Archila | Strong Buy | Strong Buy |
6/17/2024 | William Blair | Myles R Minter | Hold | Hold |
6/14/2024 | H.C. Wainwright & Co. | Douglas Tsao | Strong Buy | Strong Buy |
5/10/2024 | SVB Securities | Thomas J Smith | Strong Buy | Strong Buy |
5/9/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/9/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/26/2024 | Piper Sandler | Allison M Bratzel | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Yaron Werber | Strong Buy | Strong Buy |
3/1/2024 | JMP Securities | Jason N Butler | Not Available | Strong Buy |
3/1/2024 | Scotiabank | George Farmer | Hold | Hold |
2/15/2024 | Not Identified | Not Identified | Not Available | Hold |
10/18/2023 | Exane BNP Paribas | Victor Floch | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.32 |
ABR (Last week) | 1.32 |
# of Recs in ABR | 25 |
Average Target Price | $537.00 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 91 of 253 |
Current Quarter EPS Est: | 0.08 |